View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	0001289340
Trading Symbol	stxs
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Amendment Flag	false
Document Type	10-K
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		22,456,113
Entity Public Float			$ 19.5

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 8,501,392	$ 5,593,582
Accounts receivable, net of allowance of $379,817 and $93,478 in 2016 and 2015, respectively	4,665,959	6,376,470
Inventories	5,381,103	4,504,282
Prepaid expenses and other current assets	855,295	668,659
Total current assets	19,403,749	17,142,993
Property and equipment, net	1,086,244	1,067,321
Intangible assets, net	436,569	635,889
Other assets	39,241	31,693
Total assets	20,965,803	18,877,896
Current liabilities:
Accounts payable	2,623,010	1,840,135
Accrued liabilities	4,491,164	6,058,390
Deferred revenue	8,751,336	7,445,935
Warrants	19,787,007	794,130
Total current liabilities	35,652,517	16,138,590
Long-term debt		18,080,159
Long-term deferred revenue	522,329	2,009,198
Other liabilities	320,409	275,603
Total liabilities	36,495,255	36,503,550
Convertible Preferred stock:
Convertible Preferred stock, par value $0.001; 10,000,000 shares authorized ; 23,900 shares and zero shares outstanding at 2016 and 2015, respectively	5,960,475
Stockholders' deficit:
Common stock, par value $0.001; 300,000,000 shares authorized, 22,063,582 and 21,551,173, shares issued at 2016 and 2015, respectively	22,064	21,551
Additional paid in capital	449,939,406	448,517,472
Treasury stock, 4,015 shares at 2016 and 2015	(205,999)	(205,999)
Accumulated deficit	(471,245,398)	(465,958,678)
Total stockholders' deficit	(21,489,927)	(17,625,654)
Total liabilities and stockholders' deficit	$ 20,965,803	$ 18,877,896

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 379,817	$ 93,478
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	23,900	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	22,063,582	21,551,173
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	12 Months Ended
Statements Of Operations - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Systems	$ 5,776,843	$ 10,640,584
Disposables, service and accessories	26,387,273	27,033,940
Total revenue	32,164,116	37,674,524
Cost of revenue:
Systems	3,660,012	6,052,241
Disposables, service and accessories	3,869,321	4,385,917
Total cost of revenue	7,529,333	10,438,158
Gross margin	24,634,783	27,236,366
Operating expenses:
Research and development	5,487,609	6,252,791
Sales and marketing	15,228,193	15,850,362
General and administrative	10,345,338	10,543,741
Total operating expenses	31,061,140	32,646,894
Operating loss	(6,426,357)	(5,410,528)
Other income (expense)	(2,009,150)	1,340,057
Interest income	368	1,864
Interest expense	(2,483,752)	(3,284,168)
Gain on extinguishment of debt	5,632,171
Net loss	(5,286,720)	(7,352,775)
Deemed dividend on convertible preferred stock	(6,145,402)
Cumulative dividend on convertible preferred stock	(368,152)
Net loss available to common stockholders	$ (11,800,274)	$ (7,352,775)
Net loss per common share:
Basic	$ (0.54)	$ (0.35)
Diluted	$ (0.54)	$ (0.35)
Weighted average shares used in computing net loss per common share:
Basic	21,807,634	21,113,203
Diluted	21,807,634	21,113,203

Statements Of Convertible Preferred Stock And Stockholders' Equity - USD ($)	Convertible Preferred Stock [Member] Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member] Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Common Stock [Member]	Total
Balance, Amount at Dec. 31, 2014			$ 20,481		$ 446,241,703	$ (205,999)	$ (458,605,903)		$ (12,549,718)
Balance, Shares at Dec. 31, 2014			20,480,874
Issuance of common stock, Amount			$ 809		940,545				941,354
Issuance of common stock, Shares			809,822
Share-based compensation					1,312,319				1,312,319
Restricted stock vestings, Amount			$ 242		(242)
Restricted stock vestings, Shares			241,775
Net loss							(7,352,775)		(7,352,775)
Employee stock purchase plan, Amount			$ 19		23,147				23,166
Employee stock purchase plan, Shares			18,702
Balance, Amount at Dec. 31, 2015		$ 0	$ 21,551		448,517,472	(205,999)	(465,958,678)		(17,625,654)
Balance, Shares at Dec. 31, 2015		0	21,551,173
Issuance of common stock, Amount	$ 5,986,081			$ (1,464)				$ (1,464)
Issuance of common stock, Shares	24,000
Share-based compensation					1,365,121				1,365,121
Restricted stock vestings, Amount			$ 318		(318)
Restricted stock vestings, Shares			317,962
Net loss							(5,286,720)		(5,286,720)
Employee stock purchase plan, Amount			$ 39		33,145				33,184
Employee stock purchase plan, Shares			39,008
Beneficial conversion feature of Convertible Preferred Stock		$ (6,145,402)			6,145,402				6,145,402
Deemed dividend related to beneficial conversion feature of Convertible Preferred Stock		6,145,402			(6,145,402)				(6,145,402)
Conversion of Convertible Preferred Stock, Amount		$ (25,606)	$ 156		25,450				25,606
Conversion of Convertible Preferred Stock, Shares		(100)	155,439
Balance, Amount at Dec. 31, 2016		$ 5,960,475	$ 22,064		$ 449,939,406	$ (205,999)	$ (471,245,398)		$ (21,489,927)
Balance, Shares at Dec. 31, 2016		23,900	22,063,582

Statements Of Stockholders' Equity (Parenthetical)	12 Months Ended
Statements Of Stockholders' Equity (Parenthetical)	Dec. 31, 2016 USD ($)
Statements Of Convertible Preferred Stock And Stockholders' Equity [Abstract]
Preferred stock, discount	$ 17,649,231
Stock issuance costs	$ 159,322

Statements Of Cash Flows - USD ($)	12 Months Ended
Statements Of Cash Flows - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (5,286,720)	$ (7,352,775)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	367,611	320,301
Amortization of intangibles	199,320	299,833
Amortization of deferred finance costs	188,239	222,682
Share-based compensation	1,365,121	1,312,319
Gain on debt extinguishment	(5,632,171)
Noncash interest	485,857	449,814
Adjustment of warrants	2,009,150	(1,340,057)
Changes in operating assets and liabilities:
Accounts receivable	1,710,511	104,029
Inventories	(853,171)	1,521,995
Prepaid expenses and other current assets	(187,940)	86,944
Other assets	(7,548)	124,691
Accounts payable	782,875	(512,998)
Accrued liabilities	(1,567,226)	798,696
Deferred revenue	(181,468)	1,820,798
Other liabilities	44,806	(384,773)
Net cash used in operating activities	(6,562,754)	(2,528,501)
Cash flows from investing activities
Purchase of Fixed Asset	(410,184)	(153,151)
Net cash used in investing activities	(410,184)	(153,151)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)
Proceeds from revolving line of credit	7,650,000
Payments of revolving line of credit	(7,650,000)
Proceeds from (payments of) Healthcare Royalty Partners debt	(13,020,780)	40,413
Proceeds from issuance of stock, net of issuance costs	23,001,528	964,520
Net cash provided by (used in) financing activities	9,880,748	1,004,933
Net increase (decrease) in cash and cash equivalents	2,907,810	(1,676,719)
Cash and cash equivalents at beginning of period	5,593,582	7,270,301
Cash and cash equivalents at end of period	8,501,392	5,593,582
Supplemental disclosures of cash flow information:
Interest paid	$ 2,253,554	$ 2,974,345

Description Of Business	12 Months Ended
Description Of Business	Dec. 31, 2016
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Remote Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System (“Vdrive system”), and related devices. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. As of December 31, 2016, the Company had an installed base of 129 Niobe ES systems. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive system and the Vdrive Duo system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems, such as Niobe system, Odyssey Solution, Cardiodrive and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and European Union. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the European Union. The Company believes the cash on hand at December 31, 2016 as well as expected borrowing capacity available will be sufficient to meet its obligations as they become due in the ordinary course of business for at least 12 months following the date these financial statements are issued. However, this evaluation assumes the Company’s ability to borrow under its asset based revolving credit facility which matures on March 31, 2018. The Company expects to be able to renew this facility at similar terms, as it has successfully done so in the past. However, there is no assurance that the revolving credit facility will be renewed in a timely manner, in amounts that are sufficient to meet the Company's obligations as they become due, or on terms acceptable to the Company, or at all. The Company has sustained operating losses throughout its corporate history and expects that its 2017 expenses will exceed its 2017 gross margin. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. Accordingly, management has analyzed its planned operations to evaluate the Company’s ability to continue as a going concern. The Company’s liquidity needs will be largely determined by the success of clinical adoption within the installed base of Niobe systems as well as by new placements of capital systems. The Company’s plans, which are probable of effectively being implemented and improving the liquidity conditions, primarily include its ability to control the timing and spending of its operating expenses and raising additional funds through capital transactions. Specifically, cash outflows for operating expenses could be reduced or delayed by transitioning certain cash payments to stock payments, by reducing project expenses, or by reducing headcount. The Company also may consider raising cash through capital transactions, which could include either debt or equity financing.

Summary Of Significant Accounting Policies	12 Months Ended
Summary Of Significant Accounting Policies	Dec. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2016 or 2015. Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue The Company recognizes revenue based on the Multiple-Deliverable Revenue Arrangements guidance (“ASU 2009-13”). ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2016 or 2015 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory. Net Earnings (Loss) per Common Share Basic earnings (loss) per common share are computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed by dividing the earnings (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. In addition, the net loss attributable to common stockholders’ is adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at inception, as well as the annual dividends for the periods in which the convertible preferred stock is outstanding. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2016, the Company had 671,887 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.77 per share, 38,963,443 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.84 per share, and 37,335,618 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2016. Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. Biosense Webster Inc. accounted for $4,099,075 and $3,514,897 or 13%, and 9%, of total net revenue for the years ended December 31, 2016, and 2015, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2016. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses. Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company will adopt this guidance in the first quarter of 2017 and does not expect the adoption of ASU 2016-09 to materially impact the Company’s consolidated financial position, results of operations, equity or cash flows. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have adopted this accounting standard update. The Company’s balance sheet as of December 31, 2015 included $349,018 of deferred financing costs that were, under the new guidance, presented as a direct reduction to debt liabilities. In September 2016, the company extinguished the remainder of the debt upon an agreement entered into with Healthcare Royalty Partners. See Note 9 for additional details. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We have adopted this accounting standard update and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 and anticipates using the modified retrospective method that will result in a cumulative effect adjustment as of the date of adoption. Upon initial evaluation, management does not anticipate a significant change to its existing units of accounting which include systems, disposables and other accessories, royalty and other recurring revenue. The Company continues to evaluate other areas of the standard and its effect on the Corporation’s financial statements.

Inventory

12 Months Ended

Dec. 31, 2016

Inventory [Abstract]

Inventory

3. Inventory

Inventory consists of the following:


	December 31, 2016	December 31, 2015

Raw materials	$ 2,397,430	$ 2,065,676
Work in process	341,125	24,758
Finished goods	2,915,162	2,433,819
Reserve for obsolescence	(272,614)	(19,971)
Total inventory	$ 5,381,103	$ 4,504,282

Prepaid Expenses And Other Current Assets

12 Months Ended

Dec. 31, 2016

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	December 31, 2016	December 31, 2015

Prepaid expenses	$ 575,886	$ 454,822
Deferred financing costs	24,658	25,960
Deposits	293,992	136,583
Deferred cost of revenue	—	82,987
Total prepaid expenses and other assets	894,536	700,352
Less: Noncurrent prepaid expenses and other assets	(39,241)	(31,693)
Total current prepaid expenses and other assets	$ 855,295	$ 668,659

Certain prior year amounts have been reclassified to conform to the 2016 presentation.

Property And Equipment

12 Months Ended

Dec. 31, 2016

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	December 31,	December 31,
	2016	2015

Equipment	$ 8,397,528	$ 8,496,636
Equipment held for lease	303,412	303,412
Leasehold improvements	2,719,860	2,320,368
	11,420,800	11,120,416
Less: Accumulated depreciation	(10,334,556)	(10,053,095)
Net property and equipment	$ 1,086,244	$ 1,067,321

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2016
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets As of December 31, 2016 and 2015, the Company had total intangible assets of $3,221,069. Accumulated amortization at December 31, 2016 and 2015 was $2,784,500 and $2,585,180, respectively. Amortization expense for the years 2016 and 2015 was $199,320 and $299,833, respectively, as determined under the straight-line method. The estimated future amortization of intangible assets is $199,320 annually through July 2018, decreasing thereafter to $143,765 in 2018, $65,988 in 2019 and $27,496 through May 2020. The Company also recognized impairment charges of $443,931 during 2015 on certain 2010 intellectual property rights relating to the Company’s Odyssey Solution due to uncertainty around forecasted revenue under the Odyssey system distribution agreement beyond May 2016. The impairment is the result of a decline in forecasted revenue attributable to this intellectual property that indicated it was probable the undiscounted future cash flows would not exceed the book value of the intellectual property. As a result, the book value of the intellectual property was reduced to its fair value as estimated using a discounted cash flow analysis. The Company evaluated the discount rate in the fair value calculation with the assistance of a third party valuation specialist (Level 3).

Accrued Liabilities

12 Months Ended

Dec. 31, 2016

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	December 31,	December 31,
	2016	2015

Accrued salaries, bonus, and benefits	$ 2,452,183	$ 3,053,012
Accrued rent	965,412	1,361,379
Accrued licenses and maintenance fees	561,450	666,373
Accrued interest	-	494,703
Accrued warranties	222,845	316,835
Accrued taxes	219,017	324,226
Accrued professional services	180,450	27,140
Other	210,216	90,325
Total accrued liabilities	4,811,573	6,333,993
Less: Long term accrued liabilities	(320,409)	(275,603)
Total current accrued liabilities	$ 4,491,164	$ 6,058,390

Deferred Revenue

12 Months Ended

Dec. 31, 2016

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	December 31,	December 31,
	2016	2015

Product shipped, revenue deferred	$ 549,709	$ 366,388
Customer deposits	2,910,000	2,505,000
Deferred service and license fees	5,813,956	6,583,745
Total deferred revenue	9,273,665	9,455,133
Less: Long-term deferred revenue	(522,329)	(2,009,198)
Total current deferred revenue	$ 8,751,336	$ 7,445,935

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities

12 Months Ended

Dec. 31, 2016

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:


	December 31, 2016		December 31, 2015
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ -	$ -	$ 18,080,159	$ 18,429,177
Total debt	-	-	18,080,159	18,429,177
Less current maturities	-	-	-	-
Total long term debt	$ -	$ -	$ 18,080,159	$ 18,429,177

As of December 31, 2016, there were no contractual principal maturities of debt.

Certain prior year amounts have been reclassified to conform to the 2016 presentation.

In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of December 31, 2016 and December 31, 2015. Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3).

The revolving line of credit is secured by substantially all of the Company’s assets. The Company is required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

Revolving line of credit

The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $10.0 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018 and on May 10, 2016, the Company and the primary lender agreed to modify certain financial covenants. The amended agreement requires the Company to maintain a liquidity ratio greater than 1.50:1.00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than (no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018.

As of December 31, 2016, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of December 31, 2016 the Company had a borrowing capacity of $3.8 million based on the Company’s collateralized assets. The Company’s total liquidity as of December 31, 2016, was $12.3 million which included cash and cash equivalents of $8.5 million. As of December 31, 2016, we were in compliance with all financial covenants of this agreement and we anticipate continued compliance throughout the remainder of 2017.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners (formerly “Cowen Healthcare Royalty Partners II, L.P.”). Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the nine months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe system sales for the twelve months ended December 31, 2012. The loan was to be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Healthcare Royalty Partners was entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan was a full recourse loan, scheduled to mature on December 31, 2018, and bore interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement had been insufficient to pay all amounts of interest due on the loan, then such deficiency would have increased the outstanding principal amount on the loan. After the loan obligation was repaid, the royalties under the Biosense Agreement are paid to the Company. The loan was also secured by certain assets and intellectual property of the Company. The Agreement contained customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender.

In September 2016, the Company extinguished the remainder of the debt of $18.1 million, net of deferred financing costs of approximately $0.3 million, as well as accrued interest of $0.5 million for $13.0 million based upon an agreement entered into with Healthcare Royalty Partners. After the loan obligation was repaid, the royalties under the Biosense Agreement will again be paid to the Company. As a result of the debt extinguishment, the company recognized a net gain of $5.6 million.

Lease Obligations

12 Months Ended

Dec. 31, 2016

Lease Obligations [Abstract]

Lease Obligations

10. Lease Obligations

The Company leases its facilities under operating leases. For the years ended December 31, 2016 and 2015 rent expense was $1,187,989 and $1,205,338, respectively. The rent expense for the years ended December 31, 2016 and 2015 is net of sublease income of $91,579 and $18,912, respectively.

In January 2006, the Company moved its primary operations into its current facilities. The facility is subject to a lease which expires in December 31, 2018. Under the terms of the lease, the Company has options to renew for up to three additional years. The lease contains an escalating rent provision which the Company has straight-lined over the term of the lease.

In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138, and were accrued as a rent liability as of September 30, 2013. As of December 31, 2016, the remaining accrued costs associated with the termination were $181,601.

In the fourth quarter of 2015, the Company entered a sublease agreement to sublease 3,152 square feet of the first floor office space through December 31, 2018. In July 2016, the Company and the subtenant mutually agreed to an early termination of the sublease, effective July 31, 2016.

In August 2016 the Company entered into an agreement to sublease approximately 11,000 square feet of office space through December 31, 2018. The costs associated with the sublease were $40,972 and were accrued as a rent liability as of August 31, 2016. As of December 31, 2016, the remaining accrued costs associated with the termination were $21,286. As part of the sublease agreement, the Company will sublease an additional 16,000 square feet beginning in January 2017.

The future minimum lease payments under non-cancelable leases as of December 31, 2016 are as follows (excluding sublease income):



Year		Operating Lease Payments
2017	$	2,002,178
2018		2,037,858
2019		11,496
Total minimum lease payments		4,051,532
Less amounts representing sublease receipts		(1,510,631)
	$	2,540,901

Convertible Preferred Stock And Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Convertible Preferred Stock And Stockholders' Equity [Abstract]

Convertible Preferred Stock And Stockholders' Equity

11. Convertible Preferred Stock and Stockholders’ Equity

The holders of common stock are entitled one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the Revolving Credit Agreement. No dividends have been declared or paid as of December 31, 2016.

Convertible Preferred Stock and Warrants

On September 26, 2016, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors whereby it agreed to sell, for an aggregate purchase price of $24.0 million, (i) an aggregate of 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The transaction closed on September 29, 2016.

The Company received net proceeds from the sale of the convertible preferred stock and warrants of $23.0 million, after offering expenses. The Company used $13.0 million of the funds to satisfy in full all amounts outstanding under the Loan Agreement with Healthcare Royalty Partners, as noted above, and anticipates using the remaining proceeds for general corporate purposes.

The designations, preferences, powers and rights of the convertible preferred shares are set forth in a Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock (“Certificate of Designations”) filed with the Delaware Secretary of State. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent (6%) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Instead the value of the accrued dividends is added to the liquidation preference of the convertible preferred shares and will increase the number of shares of common stock issuable upon conversion. Each convertible preferred share is convertible at the option of the holder from and after the date of issuance with no expiration date, at an initial conversion price of $0.65 per share, subject to adjustment in the event of stock splits, dividends, mergers, sales of all or substantially all of our assets or similar transactions, subject to specified beneficial ownership issuance limitations. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a change of control as defined in the Certificate of Designations.

The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution and winding up of the Company. No such distributions or payments upon the liquidation, dissolution and winding up of the Company may be made to the holders of common stock unless and until the holders of convertible preferred shares have received the stated value of $1,000 per share plus any accrued and unpaid dividends. Until all convertible preferred shares have been converted or redeemed, no dividends may be paid on the common stock without the express written consent of the holders of a majority of the outstanding convertible preferred shares. In the event that dividends or other distributions of assets are made or paid by the Company to the holders of the common stock, the holders of convertible preferred shares are entitled to participate in such dividend or distribution on an as-converted basis.

On the date of the issuance, the fair value of the convertible preferred stock was greater than the allocated proceeds received for the Series A convertible preferred stock. As such, the Company accounted for the beneficial conversion feature under ASC 470-20, Debt with Conversion feature under ASC 470-20, Debt with Conversion and Other Options. The Company recorded a deemed dividend charge of $6.1 million for the accretion of a discount on the Series A convertible preferred stock. The deemed dividend was a non-cash transaction and is reflected below net loss to arrive at net loss available to common stockholders. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet.

The warrants issued in conjunction with the convertible preferred stock have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations. The warrants may be exercised by any holder on a cashless basis if, at any time after the date that is 180 days after the closing, the registration statement required by the Registration Rights Agreement described below is not effective and available for resale of all of the shares of common stock issuable upon exercise of such holder’s warrants. Due to the fact that the warrants are puttable upon the occurrence of certain events outside of the Company’s control, the warrants qualify as liabilities under ASC 480-10. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations. See Note 12 for additional details.

On December 2, 2016 100 shares of convertible preferred stock plus accumulated dividends were converted into 155,439 common shares.

Listing Transfer to OTCQX® Best Market

On August 2, 2016, the Company received a determination letter from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that its common stock would be delisted from The Nasdaq Capital Market (“Nasdaq”) and that suspension of trading in the shares would be effective at the open of business on August 4, 2016. The determination letter also indicated that Nasdaq would complete the delisting by filing a Form 25 Notification of Delisting with the Securities Exchange Commission, after applicable appeal periods have lapsed. The Panel made the determination to delist the Company’s common stock because the Company did not demonstrate compliance with the minimum $35 million market value of listed securities requirement for a period of ten consecutive trading days by August 1, 2016, as required by a decision previously issued by the Panel on May 2, 2016. The Company’s shares of common stock commenced trading on the OTCQX® Best Market on August 4, 2016 under the Company’s current ticker symbol of “STXS.”

Controlled Equity Offering

The Company entered into a Controlled Equity OfferingSM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company paid Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement.

There were no proceeds from the Controlled Equity Offering during the twelve months ended December 31, 2016. The Sales Agreement expired in November 2016 upon the expiration of our Registration Statement on Form S-3.

The Company has reserved shares of common stock for conversion of convertible preferred stock, exercise of warrants, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows:


	December 31,	December 31,
	2016	2015
Warrants	38,963,443	2,120,365
Series A Convertible Preferred Stock Series	47,844,562	-
Stock award plans	1,524,996	731,442
Employee Stock Purchase Plan	192,290	231,298
	88,525,291	3,083,105

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted a stock incentive plan (the 2012 Stock Incentive Plan) which was subsequently approved by the Company’s stockholders. This plan replaces the 2002 Stock Incentive Plan which expired on March 25, 2012.

The 2012 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and consultants. Options granted under the 2012 Stock Incentive Plan expire no later than ten years from the date of grant. The exercise price of each incentive stock option shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. The vesting provisions of individual options may vary, but incentive stock options generally vest 25% on the first anniversary of each grant and 1/48 per month over the next three years. Stock appreciation rights are rights to acquire a calculated number of shares of the Company’s common stock upon exercise of the rights. The number of shares to be issued is calculated as the difference between the exercise price of the right and the aggregate market value of the underlying shares on the exercise date divided by the market value as of the exercise date. Stock appreciation rights granted under the 2012 Stock Incentive Plan generally vest 25% on the first anniversary of such grant and 1/48 per month over the next three years and expire no later than ten years from the date of grant. The Company generally issues new shares upon the exercise of stock options and stock appreciation rights.

Restricted share grants are either time-based or performance-based. Time-based restricted shares generally cliff vest three years after grant. Performance-based restricted shares vest upon the achievement of performance objectives which are determined by the Company’s Board of Directors.

Restricted stock unit grants are time-based and generally vest over a period of four years. Options granted to non-employee directors expire no later than ten years from the date of grant. The exercise price of options to non-employee directors shall not be less than 100% of the fair value of the stock subject to the option on the date the option is granted. Initial grants of options to new directors generally vest over a two year period. Annual grants to directors generally vest upon the earlier of one year or the next stockholder meeting.

A summary of the option and stock appreciation rights activity for the year ended December 31, 2016 is as follows:


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2015	706,494	$1.45 - $116.40	$9.34
Granted	1,000	$1.55	$1.55
Exercised	-	-	-
Forfeited	(35,607)	$1.74 - $99.00	$19.79
Outstanding, December 31, 2016	671,887	$1.45 - $116.40	$8.77

As of December 31, 2016, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 7.06 years. Of the 671,887 options and stock appreciation rights that were outstanding as of December 31, 2016, 429,029 were vested and exercisable with a weighted average exercise price of $12.15 per share and a weighted average remaining term of 6.64 years.

A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows:


	Year Ended December 31, 2016
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $10.00		581,142		7.67 years	$	3.07		338,284	$	3.26
$30.01 - $40.00		58,745		4.03 years	$	34.86		58,745	$	34.86
$40.01 - $50.00		12,250		2.44 years	$	43.90		12,250	$	43.90
$50.01 - $60.00		12,250		1.41 years	$	54.90		12,250	$	54.90
$90.01+		7,500		0.33 years	$	113.60		7,500	$	113.60
		671,887		7.06 years	$	8.77		429,029	$	12.15

The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money at December 31, 2016. The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2016 and the intrinsic value of fully vested options and stock appreciation rights outstanding at December 31, 2016 were zero based on a closing share price of $0.65 on December 31, 2016. No options or stock appreciation rights were exercised under the Company’s stock option plans during the years ended December 31, 2015 or 2016 and the Company realized no proceeds during these periods. The weighted average grant date fair value of options and stock appreciation rights granted during the year ended December 31, 2016 was $1.55 per share.

A summary of the restricted stock unit activity for the year ended December 31, 2016 is as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2015	752,008	$2.63
Granted	862,600	$0.84
Vested	(317,962)	$2.45
Forfeited	(129,547)	$1.51
Outstanding, December 31, 2016	1,167,099	$1.48

The intrinsic value of restricted stock units outstanding at December 31, 2016 was $0.8 million based on a closing share price of $0.65 as of December 31, 2016. During the year ended December 31, 2016, the aggregate intrinsic value of restricted stock units vested was $0.3 million determined at the date of vesting.

During the fourth quarter of 2016, the Company adjusted its estimated forfeiture rates based on historical information, which resulted in an increase to share-based compensation of approximately $0.2 million for the year ended December 31, 2016.

As of December 31, 2016, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $1.8 million, net of estimated forfeitures of approximately $0.3 million. This cost will be amortized over a weighted average period of approximately one and a half years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in forfeitures.

2009 Employee Stock Purchase Plan

In 2009, the Company adopted its 2009 Employee Stock Purchase Plan (“ESPP”). In June 2014, our shareholders approved a proposal to amend the ESPP to increase the number of shares authorized for issuance under the ESPP by 250,000 shares. Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15% of their compensation of the Company’s common stock, subject to an annual maximum of $25,000, at 95% of the fair market value of the stock at the end of the purchase period, subject to certain plan limitations. As of December 31, 2016, there were 192,290 remaining shares available for issuance under the Employee Stock Purchase Plan.

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Measurements [Abstract]

Fair Value Measurements

12. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Liabilities at December 31, 2016:
Warrants issued May 2012	$	66,081	—	—	66,081
Warrants issued August 2013		151,695	—	—	151,695
Warrants issued September 2016		19,569,231	—	—	19,569,231
Total liabilities at fair value:	$	19,787,007	—	—	19,787,007
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 2012	$	143,681	—	—	143,681
Warrants issued August 2013		650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $524,083 at December 31, 2015. There were no cash equivalents invested in money market funds at December 31, 2016. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the years ended December 31, 2016 and December 31, 2015. There were no transfers in or out of Level 1 during the year ended December 31, 2016.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with the Company’s May 2012, August 2013 and September 2016 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements, the warrants did not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other income (expense)” in the Statements of Operations.

The remaining warrants from the May 2012 transaction (PIPE Warrants) expire in May 2018 and were valued using an option pricing model as of December 31, 2015 using the following assumptions: 1) volatility of 113.4%; 2) risk-free interest rate of 1.06%; and 3) a closing stock price of $0.74.

The PIPE warrants were revalued using an option pricing model as of December 31, 2016 using the following assumptions: 1) volatility of 121.12%; 2) risk-free interest rate of 1.20%; and 3) a closing stock price of $0.65.

The remaining warrants from the August 2013 transaction (Exchange warrants) expire in November 2018 and were valued using an option pricing model as of December 31, 2015 using the following assumptions: 1) volatility of 182.94%; 2) risk-free interest rate of 1.31%; and 3) a closing stock price of $0.74.

The Exchange warrants were revalued using an option pricing model as of December 31, 2016 using the following assumptions: 1) volatility of 110.32%; 2) risk-free interest rate of 1.20%; and 3) a closing stock price of $0.65.

The September 2016 warrants expire in September 2021 and were valued as of September 30, 2016 using the following assumptions: 1) volatility of 120.43%; 2) risk-free interest rate of 1.14%; and 3) a closing stock price of $0.87. These warrants were revalued using an option pricing model as of December 31, 2016 using the following assumptions: 1) volatility of 121.31%; 2) risk-free interest rate of 1.93%; and 3) a closing stock price of $0.65.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in a significantly higher (lower) liability fair value measurement.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the year ended December 31, 2016:


	Warrants issued May 2012	Warrants issued August 2013	Warrants issued September 2016	Total Liabilities
Balance at beginning of period	$ 143,681	$ 650,449	$ -	$ 794,130
Issues	-	-	17,649,231	17,649,231
Settlements	-	-	-	-
Revaluation	(77,600)	(498,754)	1,920,000	1,343,646
Balance at end of period	$ 66,081	$ 151,695	$ 19,569,231	$ 19,787,007

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Income Taxes

13. Income Taxes

The provision for income taxes consists of the following:


	Year Ended December 31,
	2016		2015
Deferred:
Federal	$	(757,955)	$	(2,529,455)
State and local		(328,867)		169,266
		(1,086,822)		(2,360,189)
Valuation allowance		1,086,822		2,360,189
	$	—	$	—

The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following:


	Year Ended December 31,
	2016		2015
U.S. statutory income tax rate	34.0	%	34.0	%
State and local taxes, net of federal tax benefit	1.0	%	1.9	%
Permanent differences between book and tax	(15.9)	%	5.6	%
Deferred tax adjustments	(5.9)	%	(9.3)	%
State rate adjustments	7.4	%	(0.1)	%
Valuation allowance	(20.6)	%	(32.1)	%
Effective income tax rate	—	%	—	%

Included in permanent differences between book and tax in the above table are the impacts of the non-deductible mark-to-market activity associated with convertible debt and warrants as well as permanent differences such as nondeductible meals and entertainment. The state rate adjustments are a result of changes in apportionment and various state rate law changes.

The components of the deferred tax asset are as follows:


	December 31,
	2016		2015
Current accruals	$	1,638,298	$	1,687,951
Deferred revenue		126,631		269,797
Depreciation and amortization		2,131,933		2,269,341
Deferred compensation		1,464,533		1,389,832
Net operating loss carryovers		33,943,745		32,744,557
Deferred tax assets		39,305,140		38,361,478
Valuation allowance		(39,000,095)		(37,912,693)
Net deferred tax assets before deferred tax liabilities		305,045		448,785
Accounting method changes		(305,045)		(448,785)
Net deferred tax assets	$	—	$	—

Under Section 382 and 383 of the Internal Revenue Code of 1986, as amended, or the “Code”, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that approximately $290 million of the Company’s federal net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets.

In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. The valuation allowance for deferred tax assets includes amounts for which subsequently recognized tax benefits will be applied directly to the contributed capital.

As of December 31, 2016, we had gross federal net operating loss carryforwards of approximately $95.6 million. The federal net operating loss carryforwards reflect accumulated book losses reduced for the 2013 IRC Section 382 ownership change limitation of $290 million and approximately $86 million of book/ tax differences and expiration of unused carryforwards. The federal net operating loss carryforwards will expire between 2030 and 2036. As of December 31, 2016, we had state net operating loss deferred tax assets of approximately $1.5 million which will expire at various dates between 2017 and 2036 if not utilized.

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 1997 forward, all tax years from 1997 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 years or less.

The Company recognizes interest accrued, if any, net of tax and penalties, related to unrecognized tax benefits as components of income tax provision as applicable. As of December 31, 2016 accrued interest and penalties were less than $0.1 million.

At December 31, 2016 and 2015, the Company had approximately $0.1 million and $0.3 million, respectively, in reserves for uncertain tax positions.

Net Loss Per Share

12 Months Ended

Dec. 31, 2016

Net Loss Per Share [Abstract]

Net Loss Per Share

14. Net Loss per Share

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations:


		Twelve months ended December 31,
		2016		2015
Net loss	$	(5,286,720)	$	(7,352,775)
Deemed dividend on convertible preferred stock		(6,145,402)		-
Cumulative dividend on convertible preferred stock		(368,152)		-
Net loss available to common stockholders	$	(11,800,274)	$	(7,352,775)

Weighted average shares used to compute basic and diluted net loss per share		21,807,634		21,113,203
Basic and diluted net loss per share	$	(0.54)	$	(0.35)

The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows:


	December 31,
	2016	2015
Shares issuable upon vesting/exercise of:
Options to purchase common stock	671,887	706,494
Series A Convertible Preferred Stock and Accumulated Dividends	37,335,618	-
Restricted stock units	1,167,099	752,008
Warrants	38,963,443	2,120,365
	78,138,047	3,578,867

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2016
Empoyee Benefit Plan [Abstract]
Employee Benefit Plan	15. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan. Employer contributions are discretionary under the 401(k) plan. Currently the Company does not match employee contributions.

Product Warranty Provisions

12 Months Ended

Dec. 31, 2016

Product Warranty Provisions [Abstract]

Product Warranty Provisions

16. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe, Odyssey and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	December 31, 2016		December 31, 2015
Warranty accrual, beginning of the fiscal period	$	316,835	$	364,548
Accrual adjustment for product warranty		103,743		171,384
Payments made		(197,733)		(219,097)
Warranty accrual, end of the fiscal period	$	222,845	$	316,835

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions In September 2016, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors whereby it agreed to sell, for an aggregate purchase price of $24.0 million, (i) an aggregate of 24,000 shares of Series A Convertible Preferred Stock, and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock (see Note 11 to the accompanying financial statements for further information). Pursuant to the transaction agreements, the Company reimbursed transaction related legal fees of $85,000 to a law firm engaged by DAFNA Capital Management. Funds managed by DAFNA Capital Management own more than 5% of the outstanding shares of the Company. Also, pursuant to the Securities Purchase Agreement, the Board appointed David Fischel, Principal at DAFNA Capital Management, and Joe Kiani, also an investor in the offering, to the Board, effective as of the closing of the Offering. Subsequent to the transaction, the Company reimbursed an additional $120,367 in transaction-related legal fees incurred by law firms engaged by these investors. In February, 2017, David Fischel was appointed acting Chief Executive Officer of Stereotaxis, Inc.

Commitments And Contingencies	12 Months Ended
Commitments And Contingencies	Dec. 31, 2016
Commitments And Contingencies [Abstract]
Commitments And Contingencies	18. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Segment Information

12 Months Ended

Dec. 31, 2016

Segment Information [Abstract]

Segment Information

19. Segment Information

The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2016 and 2015 were as follows:


	Year Ended December 31,
	2016		2015
United States	$	19,420,815	$	19,757,986
International		12,743,301		17,916,538
Total	$	32,164,116	$	37,674,524

All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events None.

Valuation And Qualifying Accounts

12 Months Ended

Dec. 31, 2016

Valuation And Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED DECEMBER 31, 2016 AND 2015


			Additions
	Balance at		Charged to
	Beginning of		Cost and				Balance at the
	Year		Expenses		Deductions		End of Year
Allowance for doubtful accounts and returns:
Year ended December 31, 2016	$	93,478	$	292,690	$	(6,351)	$	379,817
Year ended December 31, 2015	$	131,464	$	(9,463)	$	(28,523)	$	93,478

Allowance for inventories valuation:
Year ended December 31, 2016	$	19,971	$	283,441	$	(30,798)	$	272,614
Year ended December 31, 2015	$	59,634	$	42,258	$	(81,921)	$	19,971

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
Summary Of Significant Accounting Policies (Policy)	Dec. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Cash And Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments purchased with original maturities of three months or less to be cash equivalents. The Company places its cash with high-credit-quality financial institutions and invests primarily in money market accounts. No cash was restricted at December 31, 2016 or 2015.
Accounts Receivable And Allowance For Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Financial Instruments	Financial Instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt. The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 12 for disclosure of fair value measurements.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or market. The Company periodically reviews its physical inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Property And Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10-15 years. If facts and circumstances suggest that an intangible asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 2 or Level 3 inputs.
Use Of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue And Costs Of Revenue	Revenue and Costs of Revenue The Company recognizes revenue based on the Multiple-Deliverable Revenue Arrangements guidance (“ASU 2009-13”). ASU 2009-13 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices. Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future. Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Research And Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic alliances under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables at December 31, 2016 or 2015 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Share-Based Compensation	Share-Based Compensation Stock options or stock appreciation rights issued to certain non-employees are recorded at their fair value as determined in accordance with general accounting principles for share-based payments and accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services, and recognized over the service period. Deferred compensation for options granted to non-employees is remeasured on a quarterly basis through the vesting or forfeiture date. The Company utilized the Black-Scholes valuation model to determine the fair value of share-based payments at the date of previously issued grant using risk-free interest rate based on the Treasury yield on the date of the grant and expected volatility based on the Company’s historical volatility over the expected term of the option. The resulting compensation expense is recognized over the requisite service period, generally one to four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis for those shares with graded vesting. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives. Shares purchased by employees under the 2004 Employee Stock Purchase Plan were considered to be compensatory and were accounted for in accordance with general accounting principles for share-based payments. Shares purchased by employees under the 2009 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) per Common Share Basic earnings (loss) per common share are computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share are computed by dividing the earnings (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. In addition, the application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable because the Company’s unearned restricted shares do not contractually participate in its losses. In addition, the net loss attributable to common stockholders’ is adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at inception, as well as the annual dividends for the periods in which the convertible preferred stock is outstanding. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2016, the Company had 671,887 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $8.77 per share, 38,963,443 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.84 per share, and 37,335,618 shares of our common stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding for the period ended December 31, 2016.
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations Of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. Biosense Webster Inc. accounted for $4,099,075 and $3,514,897 or 13%, and 9%, of total net revenue for the years ended December 31, 2016, and 2015, respectively. No other single customer accounted for more than 10% of total revenue for the year ended December 31, 2016.
Reclassifications	Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company will adopt this guidance in the first quarter of 2017 and does not expect the adoption of ASU 2016-09 to materially impact the Company’s consolidated financial position, results of operations, equity or cash flows. In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02 - Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update. In November 2015, the FASB issued Accounting Standards Update (“ASU” or “Update”) No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We have adopted this accounting standard update and there was no impact to the results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation. In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have adopted this accounting standard update. The Company’s balance sheet as of December 31, 2015 included $349,018 of deferred financing costs that were, under the new guidance, presented as a direct reduction to debt liabilities. In September 2016, the company extinguished the remainder of the debt upon an agreement entered into with Healthcare Royalty Partners. See Note 9 for additional details. In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists or when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We have adopted this accounting standard update and provided the relevant disclosures in Note 1. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers," which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. The Company will adopt ASU 2014-09 during the first quarter of 2018 and anticipates using the modified retrospective method that will result in a cumulative effect adjustment as of the date of adoption. Upon initial evaluation, management does not anticipate a significant change to its existing units of accounting which include systems, disposables and other accessories, royalty and other recurring revenue. The Company continues to evaluate other areas of the standard and its effect on the Corporation’s financial statements.

Inventory (Tables)

12 Months Ended

Dec. 31, 2016

Inventory [Abstract]

Schedule Of Inventories


	December 31, 2016	December 31, 2015

Raw materials	$ 2,397,430	$ 2,065,676
Work in process	341,125	24,758
Finished goods	2,915,162	2,433,819
Reserve for obsolescence	(272,614)	(19,971)
Total inventory	$ 5,381,103	$ 4,504,282

Prepaid Expenses And Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2016

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets



	December 31, 2016	December 31, 2015

Prepaid expenses	$ 575,886	$ 454,822
Deferred financing costs	24,658	25,960
Deposits	293,992	136,583
Deferred cost of revenue	—	82,987
Total prepaid expenses and other assets	894,536	700,352
Less: Noncurrent prepaid expenses and other assets	(39,241)	(31,693)
Total current prepaid expenses and other assets	$ 855,295	$ 668,659

Property And Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	December 31,	December 31,
	2016	2015

Equipment	$ 8,397,528	$ 8,496,636
Equipment held for lease	303,412	303,412
Leasehold improvements	2,719,860	2,320,368
	11,420,800	11,120,416
Less: Accumulated depreciation	(10,334,556)	(10,053,095)
Net property and equipment	$ 1,086,244	$ 1,067,321

Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	December 31,	December 31,
	2016	2015

Accrued salaries, bonus, and benefits	$ 2,452,183	$ 3,053,012
Accrued rent	965,412	1,361,379
Accrued licenses and maintenance fees	561,450	666,373
Accrued interest	-	494,703
Accrued warranties	222,845	316,835
Accrued taxes	219,017	324,226
Accrued professional services	180,450	27,140
Other	210,216	90,325
Total accrued liabilities	4,811,573	6,333,993
Less: Long term accrued liabilities	(320,409)	(275,603)
Total current accrued liabilities	$ 4,491,164	$ 6,058,390

Deferred Revenue (Tables)

12 Months Ended

Dec. 31, 2016

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	December 31,	December 31,
	2016	2015

Product shipped, revenue deferred	$ 549,709	$ 366,388
Customer deposits	2,910,000	2,505,000
Deferred service and license fees	5,813,956	6,583,745
Total deferred revenue	9,273,665	9,455,133
Less: Long-term deferred revenue	(522,329)	(2,009,198)
Total current deferred revenue	$ 8,751,336	$ 7,445,935

Long-Term Debt And Credit Facilities (Tables)

12 Months Ended

Dec. 31, 2016

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Debt Outstanding


	December 31, 2016		December 31, 2015
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ -	$ -	$ 18,080,159	$ 18,429,177
Total debt	-	-	18,080,159	18,429,177
Less current maturities	-	-	-	-
Total long term debt	$ -	$ -	$ 18,080,159	$ 18,429,177

Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2016

Lease Obligations [Abstract]

Schedule Of Future Minimum Lease Payments



Year		Operating Lease Payments
2017	$	2,002,178
2018		2,037,858
2019		11,496
Total minimum lease payments		4,051,532
Less amounts representing sublease receipts		(1,510,631)
	$	2,540,901

Convertible Preferred Stock And Stockholder's Equity (Tables)

12 Months Ended

Dec. 31, 2016

Convertible Preferred Stock And Stockholders' Equity [Abstract]

Summary Of Reserved Shares Of Common Stock


	December 31,	December 31,
	2016	2015
Warrants	38,963,443	2,120,365
Series A Convertible Preferred Stock Series	47,844,562	-
Stock award plans	1,524,996	731,442
Employee Stock Purchase Plan	192,290	231,298
	88,525,291	3,083,105

Summary Of Option And Stock Appreciation Rights Activity


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2015	706,494	$1.45 - $116.40	$9.34
Granted	1,000	$1.55	$1.55
Exercised	-	-	-
Forfeited	(35,607)	$1.74 - $99.00	$19.79
Outstanding, December 31, 2016	671,887	$1.45 - $116.40	$8.77

Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price


	Year Ended December 31, 2016
							Number of		Weighted
			Weighted		Weighted		Options		Average Exercise
	Options		Average		Average		Currently		Price Per Vested
Range of Exercise Prices	Outstanding		Remaining Life		Exercise Price		Exercisable		Share
$0.00 - $10.00		581,142		7.67 years	$	3.07		338,284	$	3.26
$30.01 - $40.00		58,745		4.03 years	$	34.86		58,745	$	34.86
$40.01 - $50.00		12,250		2.44 years	$	43.90		12,250	$	43.90
$50.01 - $60.00		12,250		1.41 years	$	54.90		12,250	$	54.90
$90.01+		7,500		0.33 years	$	113.60		7,500	$	113.60
		671,887		7.06 years	$	8.77		429,029	$	12.15

Summary Of Restricted Stock Unit Activity


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2015	752,008	$2.63
Granted	862,600	$0.84
Vested	(317,962)	$2.45
Forfeited	(129,547)	$1.51
Outstanding, December 31, 2016	1,167,099	$1.48

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Measurements [Abstract]

Assets And Liabilities Measured At Fair Value On Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Liabilities at December 31, 2016:
Warrants issued May 2012	$	66,081	—	—	66,081
Warrants issued August 2013		151,695	—	—	151,695
Warrants issued September 2016		19,569,231	—	—	19,569,231
Total liabilities at fair value:	$	19,787,007	—	—	19,787,007
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 2012	$	143,681	—	—	143,681
Warrants issued August 2013		650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130

Summary Of Changes In Fair Value Of Level 3 Financial Liabilities


	Warrants issued May 2012	Warrants issued August 2013	Warrants issued September 2016	Total Liabilities
Balance at beginning of period	$ 143,681	$ 650,449	$ -	$ 794,130
Issues	-	-	17,649,231	17,649,231
Settlements	-	-	-	-
Revaluation	(77,600)	(498,754)	1,920,000	1,343,646
Balance at end of period	$ 66,081	$ 151,695	$ 19,569,231	$ 19,787,007

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Taxes [Abstract]

Schedule Of Provision For Income Taxes


	Year Ended December 31,
	2016		2015
Deferred:
Federal	$	(757,955)	$	(2,529,455)
State and local		(328,867)		169,266
		(1,086,822)		(2,360,189)
Valuation allowance		1,086,822		2,360,189
	$	—	$	—

Schedule Of Reconciliation Of Federal Income Tax Rate


	Year Ended December 31,
	2016		2015
U.S. statutory income tax rate	34.0	%	34.0	%
State and local taxes, net of federal tax benefit	1.0	%	1.9	%
Permanent differences between book and tax	(15.9)	%	5.6	%
Deferred tax adjustments	(5.9)	%	(9.3)	%
State rate adjustments	7.4	%	(0.1)	%
Valuation allowance	(20.6)	%	(32.1)	%
Effective income tax rate	—	%	—	%

Schedule Of Components Of Deferred Tax Asset


	December 31,
	2016		2015
Current accruals	$	1,638,298	$	1,687,951
Deferred revenue		126,631		269,797
Depreciation and amortization		2,131,933		2,269,341
Deferred compensation		1,464,533		1,389,832
Net operating loss carryovers		33,943,745		32,744,557
Deferred tax assets		39,305,140		38,361,478
Valuation allowance		(39,000,095)		(37,912,693)
Net deferred tax assets before deferred tax liabilities		305,045		448,785
Accounting method changes		(305,045)		(448,785)
Net deferred tax assets	$	—	$	—

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2016

Net Loss Per Share [Abstract]

Schedule Of Computation Of Basic And Diluted Earnings Per Share


		Twelve months ended December 31,
		2016		2015
Net loss	$	(5,286,720)	$	(7,352,775)
Deemed dividend on convertible preferred stock		(6,145,402)		-
Cumulative dividend on convertible preferred stock		(368,152)		-
Net loss available to common stockholders	$	(11,800,274)	$	(7,352,775)

Weighted average shares used to compute basic and diluted net loss per share		21,807,634		21,113,203
Basic and diluted net loss per share	$	(0.54)	$	(0.35)

Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share


	December 31,
	2016	2015
Shares issuable upon vesting/exercise of:
Options to purchase common stock	671,887	706,494
Series A Convertible Preferred Stock and Accumulated Dividends	37,335,618	-
Restricted stock units	1,167,099	752,008
Warrants	38,963,443	2,120,365
	78,138,047	3,578,867

Product Warranty Provisions (Tables)

12 Months Ended

Dec. 31, 2016

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	December 31, 2016		December 31, 2015
Warranty accrual, beginning of the fiscal period	$	316,835	$	364,548
Accrual adjustment for product warranty		103,743		171,384
Payments made		(197,733)		(219,097)
Warranty accrual, end of the fiscal period	$	222,845	$	316,835

Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Segment Information [Abstract]

Schedule Of Geographic Revenues


	Year Ended December 31,
	2016		2015
United States	$	19,420,815	$	19,757,986
International		12,743,301		17,916,538
Total	$	32,164,116	$	37,674,524

Description Of Business (Details)	Dec. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)
Description Of Business [Abstract]
Installed base \| item	129
Cumulative net losses \| $	$ (471,245,398)	$ (465,958,678)

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Sep. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted cash	$ 0	$ 0
Research and development receivables	$ 0	$ 0
Exercise price of warrants			$ 0.70
Reserved shares of common stock	88,525,291	3,083,105
Revenues	$ 32,164,116	$ 37,674,524
Deferred financing costs		$ 349,018
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	37,335,618
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Property and equipment, estimated useful lives	3 years
Intangible assets, estimated useful lives	10 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Property and equipment, estimated useful lives	10 years
Intangible assets, estimated useful lives	15 years
Deferred Service And License Fees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred revenue, amortization period	1 year
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and stock appreciation rights outstanding	671,887	706,494
Weighted average exercise price	$ 8.77	$ 9.34
Stock Options And Stock Appreciation Rights [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	1 year
Stock Options And Stock Appreciation Rights [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, requisite service period	4 years
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable upon exercise of outstanding warrants	38,963,443
Exercise price of warrants	$ 0.84
Reserved shares of common stock	38,963,443	2,120,365
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	1,167,099	752,008
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested restricted shares	0
Biosense Webster Inc [Member] \| Net Revenue [Member] \| Customer Concentration Risk [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Revenues	$ 4,099,075	$ 3,514,897
Revenues percentage	13.00%	9.00%

Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory [Abstract]
Raw materials	$ 2,397,430	$ 2,065,676
Work in process	341,125	24,758
Finished goods	2,915,162	2,433,819
Reserve for obsolescence	(272,614)	(19,971)
Total inventory	$ 5,381,103	$ 4,504,282

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 575,886	$ 454,822
Deferred financing costs	24,658	25,960
Deposits	293,992	136,583
Deferred cost of revenue		82,987
Total prepaid expenses and other assets	894,536	700,352
Less: Noncurrent prepaid expenses and other assets	(39,241)	(31,693)
Total current prepaid expenses and other assets	$ 855,295	$ 668,659

Property And Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 11,420,800	$ 11,120,416
Less: Accumulated depreciation	(10,334,556)	(10,053,095)
Net property and equipment	1,086,244	1,067,321
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,397,528	8,496,636
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,719,860	$ 2,320,368

Intangible Assets (Details) - USD ($)	12 Months Ended
Intangible Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Intangible Assets [Abstract]
Total intangible assets	$ 3,221,069
Accumulated amortization	2,784,500	$ 2,585,180
Amortization expense	199,320	299,833
Future amortization expense in 2017	199,320
Future amortization expense through January - July 2018	199,320
Future amortization expense August - December 2018	143,765
Future amortization expense in 2019	65,988
Future amortization expense in 2020	$ 27,496
Impairment charges		$ 443,931

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,452,183	$ 3,053,012
Accrued rent	965,412	1,361,379
Accrued licenses and maintenance fees	561,450	666,373
Accrued interest		494,703
Accrued warranties	222,845	316,835	$ 364,548
Accrued taxes	219,017	324,226
Accrued professional services	180,450	27,140
Other	210,216	90,325
Total accrued liabilities	4,811,573	6,333,993
Less: Long term accrued liabilities	(320,409)	(275,603)
Total current accrued liabilities	$ 4,491,164	$ 6,058,390

Deferred Revenue (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 9,273,665	$ 9,455,133
Less: Long-term deferred revenue	(522,329)	(2,009,198)
Total current deferred revenue	8,751,336	7,445,935
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	549,709	366,388
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	2,910,000	2,505,000
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 5,813,956	$ 6,583,745

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities (Narrative) (Details)				1 Months Ended	12 Months Ended
	Jan. 31, 2013 USD ($)	Aug. 08, 2012 USD ($)	Nov. 30, 2011 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Total liquidity					$ 12,300,000
Cash and cash equivalents					8,501,392	$ 5,593,582	$ 7,270,301
Line of credit facility, repayments					7,650,000
Deferred financing costs						349,018
Accrued interest						$ 494,703
Gain on debt extinguishment					5,632,171
Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount of debt extinguished				$ 18,100,000
Deferred financing costs				300,000
Accrued interest				500,000
Payments of debt				$ 13,000,000	$ 13,000,000
Term Loan [Member] \| Healthcare Royalty Partners Debt [Member]
Debt Instrument [Line Items]
Amount borrowed	$ 2,500,000	$ 2,500,000	$ 15,000,000
Additional amount which may be borrowed			$ 5,000,000
Percentage of royalties entitled to receive			100.00%
Maturity date					Dec. 31, 2018
Annual interest rate			16.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					$ 10,000,000
Line of credit facility, maturity date					Mar. 31, 2018
Minimum tangible net worth requirement, period one					$ (24,000,000)
Minimum tangible net worth requirement, period two					(24,500,000)
Line of credit facility, amount outstanding					0
Line of credit facility, current borrowing capacity					$ 3,800,000
Minimum [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Liquidity ratio					1.50

Long-Term Debt And Credit Facilities (Schedule Of Debt Outstanding) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total long term debt		$ 18,080,159
Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt		18,080,159
Less current maturities
Total long term debt		18,080,159
Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt		18,429,177
Less current maturities
Total long term debt		18,429,177
Healthcare Royalty Partners Debt [Member] \| Term Loan [Member] \| Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt		18,080,159
Healthcare Royalty Partners Debt [Member] \| Term Loan [Member] \| Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt		$ 18,429,177

Lease Obligations (Narrative) (Details)	12 Months Ended
Lease Obligations (Narrative) (Details)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) ft²	Aug. 31, 2016 USD ($) ft²	Sep. 30, 2013 USD ($) ft²
Rent expense	$ 1,187,989	$ 1,205,338
Sublease income	$ 91,579	18,912
Lease renewal term	3 years
Accrued costs of rent liability	$ 965,412	$ 1,361,379
Unimproved [Member]
Square feet of leased space \| ft²				13,000
Accrued lease termination costs remaining	181,601
Accrued costs of rent liability				$ 515,138
Office [Member]
Square feet of leased space \| ft²		3,152
Office Sublease [Member]
Square feet of leased space \| ft²			11,000
Accrued lease termination costs remaining	$ 21,286
Accrued costs of rent liability			$ 40,972
Sublease expiration date	Dec. 31, 2018
Office Sublease, January 2017 [Member]
Square feet of leased space \| ft²			16,000

Lease Obligations (Schedule of Future Minimum Lease Payments) (Details)	Dec. 31, 2016 USD ($)
Lease Obligations [Abstract]
2017	$ 2,002,178
2018	2,037,858
2019	11,496
Total minimum lease payments	4,051,532
Less amounts representing sublease receipts	(1,510,631)
Net minimum lease payments	$ 2,540,901

Convertible Preferred Stock And Stockholders' Equity (Narrative) (Details)		1 Months Ended			12 Months Ended
	Sep. 29, 2016 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Jun. 30, 2014 shares	May 31, 2014 USD ($)	Dec. 31, 2016 USD ($) $ / shares item shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2009 USD ($)
Shareholders' Equity and Share-based Payments [Line Items]
Votes per share \| item					1
Dividends declared					$ 0
Dividends paid					$ 0
Proceeds from preferred stock and warrants issued, gross	$ 24,000,000
Preferred stock, shares issued \| shares	24,000
Preferred stock, par value \| $ / shares					$ 0.001	$ 0.001
Preferred Stock, Liquidation Preference, Value					$ 1,000
Common stock issuable from warrants \| shares	36,923,078
Proceeds from preferred stocks and warrants, net	$ 23,000,000
Preferred stock dividend rate					6.00%
Preferred stock, conversion price \| $ / shares					$ 0.65
Preferred stock redemption, triggering event, Percent of common stock sold threshold					50.00%
Preferred stock, Accretion of dicount					$ 6,100,000
Exercise price of warrants \| $ / shares	$ 0.70
Adjustment for forfeiture rate					200,000
Total compensation cost not yet recognized					1,800,000
Estimated forfeitures					$ 300,000
Weighted average amortization period of total compensation cost not yet recognized					1 year 6 months
Convertible Preferred Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares converted \| shares					100
Common Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Shares issued in conversion \| shares					155,439
2009 Employee Stock Purchase Plan [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value							95.00%
Increase in number of shares authorized for issuance under the Plan \| shares			250,000
Eligible employees new purchase period					3 months
Maximum percentage of compensation eligible employees can use to purchase common stock							15.00%
Compensation amount eligible employees can use to purchase common stock, maximum							$ 25,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent							95.00%
Remaining shares available for issuance \| shares					192,290
Sales Agreement [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Aggregate gross sales price				$ 18,000,000
Commission percentage of gross proceeds				3.00%
Stock Options And Stock Appreciation Rights [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term					10 years
Weighted average remaining contractual life					7 years 22 days
Options and stock appreciation rights vested and exercisable \| shares					429,029
Options and stock appreciation rights weighted average exercise price \| $ / shares					$ 12.15
Options and stock appreciation rights weighted average remaining term					6 years 7 months 21 days
Options and stock appreciation rights intrinsic value					$ 0
Proceeds from options and stock appreciation rights exercised					$ 0	$ 0
Weighted average grant date fair value of options and stock appreciation rights granted \| $ / shares					$ 1.55
Share price \| $ / shares					$ 0.65
Stock Options And Stock Appreciation Rights [Member] \| Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage					25.00%
Stock Options And Stock Appreciation Rights [Member] \| Tranche Two [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage					2.0833%
Options vesting period					3 years
Stock Options And Stock Appreciation Rights [Member] \| Director [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term					10 years
Stock Options And Stock Appreciation Rights [Member] \| Director [Member] \| Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period					2 years
Stock Options And Stock Appreciation Rights [Member] \| Director [Member] \| Tranche Two [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period					1 year
Stock Options And Stock Appreciation Rights [Member] \| Minimum [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value					100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					100.00%
Stock Options And Stock Appreciation Rights [Member] \| Minimum [Member] \| Director [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price as percentage of fair value					100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent					100.00%
Warrants [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Exercise price of warrants \| $ / shares					$ 0.84
Stock Appreciation Rights [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options expiration term					10 years
Stock Appreciation Rights [Member] \| Tranche One [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage					25.00%
Stock Appreciation Rights [Member] \| Tranche Two [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting percentage					2.0833%
Options vesting period					3 years
Restricted Stock [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period					3 years
Restricted shares outstanding \| shares					0
Restricted Stock Units [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Options vesting period					4 years
Intrinsic value of restricted awards outstanding					$ 800,000
Intrinsic value of restricted awards vested					$ 300,000
Restricted shares outstanding \| shares					1,167,099	752,008
Share price \| $ / shares					$ 0.65
Healthcare Royalty Partners Debt [Member]
Shareholders' Equity and Share-based Payments [Line Items]
Payments of debt		$ 13,000,000			$ 13,000,000

Convertible Preferred Stock And Stockholders' Equity (Summary Of Reserved Shares Of Common Stock) (Details) - shares	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	88,525,291	3,083,105
Series A Convertible Preferred Stock Series [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	47,844,562
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	38,963,443	2,120,365
Stock Award Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	1,524,996	731,442
2009 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reserved shares of common stock	192,290	231,298

Convertible Preferred Stock And Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - Stock Options And Stock Appreciation Rights [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2015	706,494
Number of Options/SARs, Granted	1,000
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(35,607)
Number of Options/SARs, Outstanding, December 31, 2016	671,887	706,494
Weighted Average Exercise Price per Share, Outstanding, December 31, 2015	$ 9.34
Weighted Average Exercise Price per Share, Granted	1.55
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	19.79
Weighted Average Exercise Price per Share, Outstanding, December 31, 2016	8.77	$ 9.34
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit		1.45
Range of Exercise Price, Upper Limit		$ 116.40
$1.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Weighted Average Exercise Price per Share, Granted	1.55
$1.74 - $99.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	1.74
Range of Exercise Price, Upper Limit	99.00
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	1.45
Range of Exercise Price, Upper Limit	$ 116.40

Convertible Preferred Stock And Stockholders' Equity (Summary Of Options And Stock Appreciation Rights Outstanding By Range Of Exercise Price) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	671,887	706,494
Weighted Average Remaining Life	7 years 22 days
Weighted Average Exercise Price	$ 8.77	$ 9.34
Number of Options Currently Exercisable	429,029
Weighted Average Exercise Price per Vested Share	$ 12.15
$0.00 - $10.00 [Member] \| Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	0.00
Range of Exercise Price, Upper Limit	$ 10.00
Options Outstanding	581,142
Weighted Average Remaining Life	7 years 8 months 1 day
Weighted Average Exercise Price	$ 3.07
Number of Options Currently Exercisable	338,284
Weighted Average Exercise Price per Vested Share	$ 3.26
$30.01 - $40.00 [Member] \| Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	30.01
Range of Exercise Price, Upper Limit	$ 40.00
Options Outstanding	58,745
Weighted Average Remaining Life	4 years 11 days
Weighted Average Exercise Price	$ 34.86
Number of Options Currently Exercisable	58,745
Weighted Average Exercise Price per Vested Share	$ 34.86
$40.01 - $50.00 [Member] \| Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	40.01
Range of Exercise Price, Upper Limit	$ 50.00
Options Outstanding	12,250
Weighted Average Remaining Life	2 years 5 months 9 days
Weighted Average Exercise Price	$ 43.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 43.90
$50.01 - $60.00 [Member] \| Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	50.01
Range of Exercise Price, Upper Limit	$ 60.00
Options Outstanding	12,250
Weighted Average Remaining Life	1 year 4 months 28 days
Weighted Average Exercise Price	$ 54.90
Number of Options Currently Exercisable	12,250
Weighted Average Exercise Price per Vested Share	$ 54.90
$90.01+ [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Price, Lower Limit	$ 90.01
$90.01+ [Member] \| Stock Options And Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding	7,500
Weighted Average Remaining Life	3 months 29 days
Weighted Average Exercise Price	$ 113.60
Number of Options Currently Exercisable	7,500
Weighted Average Exercise Price per Vested Share	$ 113.60

Convertible Preferred Stock And Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2015 \| shares	752,008
Number of Restricted Stock Units, Granted \| shares	862,600
Number of Restricted Stock Units, Vested \| shares	(317,962)
Number of Restricted Stock Units, Forfeited \| shares	(129,547)
Number of Restricted Stock Units, Outstanding, December 31, 2016 \| shares	1,167,099
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2015 \| $ / shares	$ 2.63
Weighted Average Grant Date Fair Value per Unit, Granted \| $ / shares	0.84
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	2.45
Weighted Average Grant Date Fair Value per Unit, Forfeited \| $ / shares	1.51
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2016 \| $ / shares	$ 1.48

Fair Value Measurements (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			$ 524,083
Financial assets			524,083
Financial liabilities		$ 19,787,007	794,130
Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Volatility rate	120.43%	121.31%
Risk-free interest rate	1.14%	1.93%
Closing stock price	$ 0.87	$ 0.65
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents			524,083
Transfers into Level 1		$ 0
Transfers out of Level 1		0
Financial assets			524,083
Significant Other Observable Inputs (Level 2) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Financial assets
Financial liabilities
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date		May 01, 2018
Volatility rate		121.12%	113.40%
Risk-free interest rate		1.20%	1.06%
Closing stock price		$ 0.65	$ 0.74
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities		$ 19,787,007	$ 794,130
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant expiration date		Nov. 01, 2018
Volatility rate		110.32%	182.94%
Risk-free interest rate		1.20%	1.31%
Closing stock price		$ 0.65	$ 0.74

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		$ 524,083
Total assets at fair value		524,083
Warrants issued	$ 19,787,007	794,130
Total liabilities at fair value	19,787,007	794,130
Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	66,081	143,681
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	151,695	650,449
Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	19,569,231
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents		524,083
Total assets at fair value		524,083
Significant Other Observable Inputs (Level 2) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] \| Recurring [Member] \| Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] \| Recurring [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] \| Recurring [Member] \| Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	19,787,007	794,130
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member] \| Warrants Issued May 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	66,081	143,681
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	151,695	$ 650,449
Significant Unobservable Inputs (Level 3) [Member] \| Recurring [Member] \| Warrants Issued September 2016 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 19,569,231

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	12 Months Ended
	Dec. 31, 2016 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$ 794,130
Issues	17,649,231
Settlements
Revaluation	1,343,646
Balance at end of period	19,787,007
Warrants Issued May 2012 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	143,681
Issues
Settlements
Revaluation	(77,600)
Balance at end of period	66,081
Warrants Issued August 2013 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	650,449
Issues
Settlements
Revaluation	(498,754)
Balance at end of period	151,695
Warrants Issued September 2016 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issues	17,649,231
Settlements
Revaluation	1,920,000
Balance at end of period	$ 19,569,231

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Valid portion of valuation allowance percentage	100.00%
Permanent book/tax differences and expirations	$ 86,000,000
Accrued interest and penalties	100,000
Reserves for uncertain tax positions	100,000	$ 300,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryovers expiring unused	290,000,000
Operating loss carryforwards	$ 95,600,000
Federal [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2030
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2036
Federal [Member] \| Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Tax year subject to examination	1997
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 1,500,000
Number of prior years subject to examination	10 years
State [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2017
State [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2036

Income Taxes (Schedule Of Provision For Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Federal	$ (757,955)	$ (2,529,455)
State and local	(328,867)	169,266
Total deferred income tax expense (benefit)	(1,086,822)	(2,360,189)
Valuation allowance	1,086,822	2,360,189
Income tax benefit

Income Taxes (Schedule Of Reconciliation Of Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
U.S. statutory income tax rate	34.00%	34.00%
State and local taxes, net of federal tax benefit	1.00%	1.90%
Permanent differences between book and tax	(15.90%)	5.60%
Deferred tax adjustments	(5.90%)	(9.30%)
State rate adjustments	7.40%	(0.10%)
Valuation allowance	(20.60%)	(32.10%)
Effective income tax rate

Income Taxes (Schedule Of Components Of Deferred Tax Asset) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Abstract]
Current accruals	$ 1,638,298	$ 1,687,951
Deferred revenue	126,631	269,797
Depreciation and amortization	2,131,933	2,269,341
Deferred compensation	1,464,533	1,389,832
Net operating loss carryovers	33,943,745	32,744,557
Deferred tax assets	39,305,140	38,361,478
Valuation allowance	(39,000,095)	(37,912,693)
Net deferred tax assets before deferred tax liabilities	305,045	448,785
Accounting method changes	(305,045)	(448,785)
Net deferred tax assets

Net Loss Per Share (Schedule Of Computation Of Basic And Diluted Earnings Per Share) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Net Loss Per Share [Abstract]
Net loss	$ (5,286,720)	$ (7,352,775)
Deemed dividend on convertible preferred stock	(6,145,402)
Cumulative dividend on convertible preferred stock	(368,152)
Net loss available to common stockholders	$ (11,800,274)	$ (7,352,775)
Weighted average shares used to compute basic and diluted net loss per share	21,807,634	21,113,203
Basic and diluted net loss per share	$ (0.54)	$ (0.35)

Net Loss Per Share (Schedule Of Anti-Dilutive Securities Excluded From Computation Of Diluted Earnings Per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	78,138,047	3,578,867
Stock Options And Stock Appreciation Rights [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	671,887	706,494
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	37,335,618
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,167,099	752,008
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	38,963,443	2,120,365

Employee Benefit Plan (Details)	12 Months Ended
Employee Benefit Plan (Details)	Dec. 31, 2016
Empoyee Benefit Plan [Abstract]
Employer match of employee contributions	0.00%

Product Warranty Provisions (Details) - USD ($)	12 Months Ended
Product Warranty Provisions (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Product Warranty Provisions [Abstract]
Standard product warranty coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 316,835	$ 364,548
Accrual adjustment for product warranty	103,743	171,384
Payments made	(197,733)	(219,097)
Warranty accrual, end of the fiscal period	$ 222,845	$ 316,835

Related Party Transactions (Narrative) (Details) - USD ($)		1 Months Ended	3 Months Ended
	Sep. 29, 2016	Sep. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Proceeds from preferred stock and warrants issued, gross	$ 24,000,000
Preferred stock, shares issued	24,000
Common stock issuable from warrants	36,923,078
DAFNA Capital Management [Member]
Related Party Transaction [Line Items]
Legal fees related to stock issuance		$ 85,000
DAFNA Capital Management And Joe Kiani [Member]
Related Party Transaction [Line Items]
Legal fees related to stock issuance			$ 120,367
DAFNA Capital Management [Member] \| Stereotaxis Inc. [Member]
Related Party Transaction [Line Items]
Ownership interest		5.00%

Segment Information (Details) - USD ($)	12 Months Ended
Segment Information (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Total revenue	$ 32,164,116	$ 37,674,524
Operating Segments [Member] \| United States [Member]
Total revenue	19,420,815	19,757,986
Operating Segments [Member] \| International [Member]
Total revenue	$ 12,743,301	$ 17,916,538

Valuation And Qualifying Accounts (Details) - USD ($)	12 Months Ended
Valuation And Qualifying Accounts (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Allowance For Doubtful Accounts And Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 93,478	$ 131,464
Additions Charged to Cost and Expenses	292,690	(9,463)
Deductions	(6,351)	(28,523)
Balance at the End of Year	379,817	93,478
Allowance For Inventories Valuation [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	19,971	59,634
Additions Charged to Cost and Expenses	283,441	42,258
Deductions	(30,798)	(81,921)
Balance at the End of Year	$ 272,614	$ 19,971